Citations

Clear

2391 citation(s) found for "Xu, Lin".

Outcomes in primary cutaneous diffuse large B‐cell lymphoma, leg type
Kraft, Robert M. , Ansell, Stephen M. , Wang, Yucai , Thanarajasingam, Gita , Macon, William R. , Inwards, David J. , Porrata, Luis F. , Micallef, Ivana N. , Thompson, Carrie A. , Johnston, Patrick B. , Nowakowski, Grzegorz S. , Lin, Yi , Wang, Yucai , Lester, Scott C. , Macon, William, Witzig, T.E. , Thompson, Carrie A , Paludo, Jonas , Lin, Yi , Villasboas, José C. , Bennani, N. Nora , Habermann, Thomas M. , Witzig, Thomas E. , Paludo, Jonas

Mayo Clinic

Hematological Oncology | August 28, 2021 | Volume: 39 | Issue: 5 | Pages: 658-663

10.1002/hon.2919 | PMID 34453851 Get It

Abstract Primary cutaneous diffuse large B‐cell lymphoma, leg type (PCDLBCL, LT) is a rare, aggressive lymphoma characterized by skin involvement predominantly in the lower extremities. Immunochemotherapy with or without involved‐site radiation therapy (ISRT) is considered standard front‐line therapy. Over‐expression of PD‐L1/PD‐L2 is seen in a high proportion of PCDLBCL, LT cases, but efficacy of immune checkpoint inhibitors (ICI) in relapsed/refractory, PCDLBCL, LT has not been thoroughly studied. We conducted a retrospective cohort study of patients diagnosed with PCDLBCL, LT seen at Mayo Clinic from 1 January 2000 to 31 December 2020. Using the Kaplan–Meier method, we calculated progression‐free survival, duration of response, and overall survival in patients who received front‐line rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R‐CHOP) with and without ISRT, and salvage ICI therapy for relapsed/refractory disease. A total of 28 patients with PCDLBCL, LT were identified. The median PFS in patients treated with R‐CHOP plus ISRT was 58 months (95% CI: 18–112) compared to 14 months (95% CI: 5–not reached; p = 0.04) in those treated with R‐CHOP without ISRT. The median PFS from salvage ICI therapy was 10 months (95% CI: 4–not reached), and median DOR from salvage ICI therapy was 23 months [95% CI: 4–26]. R‐CHOP with ISRT had a significantly longer median PFS compared to R‐CHOP without ISRT as front‐line therapy for PCDLBCL, LT. ICIs may have a role in treating relapsed/refractory disease as reasonable activity in heavily pre‐treated patients was observed in this study.
Update on the Basic Science Concepts and Applications of Adipose-Derived Stem Cells in Hand and Craniofacial Surgery
Lynch, Evan B. , Anderson, Wes, DeCoster, Ryan , Bonaroti, Alisha R., Vyas, Krishna S. , Vásconez, Henry C., Lin, Kant Y., Anderson, W Matthew, DeCoster, Ryan C , Bourne, Debra A, Bourne, Debra A.

Mayo Clinic

Plastic & Reconstructive Surgery | August 25, 2021 | Volume: 148 | Issue: 3 | Pages: 475e-486e

10.1097/prs.0000000000008279 | PMID 34432707 Get It

Summary: Adipose-derived stem cell therapy offers plastic surgeons a novel treatment alternative for conditions with few therapeutic options. Adipose-derived stem cells are a promising treatment because of their broad differentiation potential, capacity for self-renewal, and ease of isolation. Over the past decade, plastic surgeons have attempted to harness adipose-derived stem cells’ unique cellular characteristics to improve the survival of traditional fat grafting procedures, a process known as cell-assisted lipotransfer. However, the full implications of cell-assisted lipotransfer in clinical practice remain incompletely understood, stressing the urgent need to assess the scientific evidence supporting adipose-derived stem cell–based interventions. Furthermore, with the strict regulatory climate surrounding tissue explantation therapies, reviewing the safety and efficacy of these treatments will clarify their regulatory viability moving forward. In this report, the authors provide a comprehensive, up-to-date appraisal of best evidence-based practices supporting adipose-derived stem cell–derived therapies, highlighting the known mechanisms behind current clinical applications in tissue engineering and regenerative medicine specific to plastic and reconstructive surgery. The authors outline best practices for the harvest and isolation of adipose-derived stem cells and discuss why procedure standardization will elucidate the scientific bases for their broad use. Finally, the authors discuss challenges posed by U.S. Food and Drug Administration oversight of these cell-based therapies and examine the role of adipose-derived stem cell–based applications in the future of plastic surgery.
Social and Behavioral Determinants of Health in the Era of Artificial Intelligence with Electronic Health Records: A Scoping Review
Bompelli, Anusha , Wang, Yanshan , Wan, Ruyuan , Singh, Esha, Zhou, Yuqi, Xu, Lin , Oniani, David , Kshatriya, Bhavani Singh Agnikula, Balls‐Berry, Joyce E. , Zhang, Rui , Balls-Berry, Joyce Joy E , Wang, Yanshan , Bompelli, Anusha , Wan, Ruyuan , Singh, Esha, Zhou, Yuqi, Xu, Lin , Oniani, David , Kshatriya, Bhavani Singh Agnikula, Zhang, Rui

Mayo Clinic

Health Data Science | August 24, 2021 | Volume: 2021 | Issue: No issue available | Pages: No page available

10.34133/2021/9759016 | PMID 38487504 Get It

Background . There is growing evidence that social and behavioral determinants of health (SBDH) play a substantial effect in a wide range of health outcomes. Electronic health records (EHRs) have been widely employed to conduct observational studies in the age of artificial intelligence (AI). However, there has been limited review into how to make the most of SBDH information from EHRs using AI approaches. Methods . A systematic search was conducted in six databases to find relevant peer-reviewed publications that had recently been published. Relevance was determined by screening and evaluating the articles. Based on selected relevant studies, a methodological analysis of AI algorithms leveraging SBDH information in EHR data was provided. Results . Our synthesis was driven by an analysis of SBDH categories, the relationship between SBDH and healthcare-related statuses, natural language processing (NLP) approaches for extracting SBDH from clinical notes, and predictive models using SBDH for health outcomes. Discussion . The associations between SBDH and health outcomes are complicated and diverse; several pathways may be involved. Using NLP technology to support the extraction of SBDH and other clinical ideas simplifies the identification and extraction of essential concepts from clinical data, efficiently unlocks unstructured data, and aids in the resolution of unstructured data-related issues. Conclusion . Despite known associations between SBDH and diseases, SBDH factors are rarely investigated as interventions to improve patient outcomes. Gaining knowledge about SBDH and how SBDH data can be collected from EHRs using NLP approaches and predictive models improves the chances of influencing health policy change for patient wellness, ultimately promoting health and health equity.
Age defining immune effector cell associated neurotoxicity syndromes in aggressive large B cell lymphoma patients treated with axicabtagene ciloleucel
Wudhikarn, Kitsada , Bansal, Radhika , Khurana, Arushi , Hathcock, Matthew , Braksick, Sherri A. , Wang, Yucai , Johnston, Patrick B. , Ansell, Stephen M. , Lin, Yi , Paludo, Jonas , Wang, Yucai , Ansell, Stephen M , Lin, Yi , Bennani, N. Nora , Paludo, Jonas , Villasboas, José C.

Mayo Clinic

American Journal of Hematology | August 23, 2021 | Volume: 96 | Issue: 11 | Pages: No page available

10.1002/ajh.26330 | PMID 34424554 Get It

Wilms Tumor (Nephroblastoma), Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Anderson, Clarke, Cook, Shelly, Gow, Kenneth W. , Hiniker, Susan M. , Jasty‐Rao, Rama, Lin, Chi , Lovvorn, Harold N. , MacEwan, Iain, Martínez-Agosto, Julián A. , Mullen, Elizabeth A. , Murphy, Erin S. , Ranalli, Mark , Rhee, Daniel S. , Tracy, Elisabeth T. , Vern-Gross, T.Z., Walsh, Michael F. , Wickiser, Jonathan E., Zapala, Matthew A. , Berardi, Ryan A., Hughes, Miranda, Vern-Gross, Tamara, Tracy, Elisabeth T , Balis, Frank M. , Green, Daniel M. , Dhillon, Jasreman , Rokitka, Denise A. , Walz, Amy L.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | August 20, 2021 | Volume: 19 | Issue: 8 | Pages: 945-977

10.6004/jnccn.2021.0037 | PMID 34416707 Get It

The NCCN Guidelines for Wilms Tumor focus on the screening, diagnosis, staging, treatment, and management of Wilms tumor (WT, also known as nephroblastoma). WT is the most common primary renal tumor in children. Five-year survival is more than 90% for children with all stages of favorable histology WT who receive appropriate treatment. All patients with WT should be managed by a multidisciplinary team with experience in managing renal tumors; consulting a pediatric oncologist is strongly encouraged. Treatment of WT includes surgery, neoadjuvant or adjuvant chemotherapy, and radiation therapy (RT) if needed. Careful use of available therapies is necessary to maximize cure and minimize long-term toxicities. This article discusses the NCCN Guidelines recommendations for favorable histology WT.
A systems‐level analysis highlights microglial activation as a modifying factor in common epilepsies
Altmann, André , Ryten, Mina , Nunzio, Martina Di , Ravizza, Teresa , Reynolds, Regina H. , Somani, Alyma, Bacigaluppi, Marco , Iori, Valentina , Sapia, Rossella Di , Cerovic, Milica , Palma, Eleonora , Ruffolo, Gabriele , Botía, Juan A. , Absil, Julie , Alhusaini, Saud , Alvim, Marina K. M. , Auvinen, Pia, Bartolini, Emanuele , Bender, Benjamin , Bergo, Felipe P. G. , Bernardes, Tauana, Bernasconi, Andrea , Bernasconi, Neda , Bernhardt, Boris C. , Blackmon, Karen , Braga, Bárbara , Caligiuri, Maria Eugenia , Calvo, Anna, Carr, Sarah J. A. , Cavalleri, Gianpiero L. , Chen, Jian , Chen, Shuai , Cherubini, Andrea , Concha, Luis , David, Philippe, Delanty, Norman, Depondt, Chantal, Doherty, Colin P. , Domín, Martin , Foley, Sonya , França, Wendy, Gambardella, Antonio , Guerrini, Renzo , Hamandi, Khalid , Hibar, Derrek P., Isaev, Dmitry , Jahanshad, Neda , Kälviäinen, Reetta , Keller, Simon S. , Kotikalapudi, Raviteja , Kwan, Patrick , Langner, Sönke , Lenge, Matteo , Martin, Pascal , Meletti, Stefano , Morita‐Sherman, Marcia , Pariente, José C. , Richardson, Mark P. , Rummel, Christian , Saavalainen, Taavi, Semmelroch, Mira , Striano, Pasquale, Thesen, Thomas , Thomas, Rhys H. , Tondelli, Manuela , Vaudano, Anna Elisabetta , Vivash, Lucy , Podewils, Felix von , Wagner, Jan , Weber, Bernd , Wiest, Roland , Yasuda, Clarissa Lin , Zhang, Junsong , Group, ENIGMA‐Epilepsy Working, Leu, Costin , Avberšek, Andreja , Whelan, Christopher D. , Thompson, Paul M. , McDonald, Carrie R. , Di Sapia, Rossella , Bender, Benjamin , Severino, Mariasavina , Thom, Maria , Yasuda, Clarissa L , Doherty, Colin P , Cavalleri, Gianpiero L , Weber, Bernd , Thompson, Paul M , Richardson, Mark P , Guerrini, Renzo , Thomas, Rhys H , Leu, Costin , Tolomeo, Daniele , Micotti, Edoardo , Bargalló, Núria , Carlson, Chad , Cendes, Fernando , Devinsky, Orrin , Focke, Niels K. , Jackson, Graeme D. , Kochunov, Peter V , Kowalczyk, Magdalena A. , Kuzniecky, Ruben , Labate, Angelo , Liu, Min , Mascalchi, Mario , Morita, Márcia Elisabete , O’Brien, Terence J. , Rodríguez‐Cruces, Raúl , Tortora, Domenico , Zhang, Guohao , Group, ENIGMA‐Epilepsy Working, Vezzani, Annamaria , Sisodiya, Sanjay

Mayo Clinic

Neuropathology and Applied Neurobiology | August 13, 2021 | Volume: 48 | Issue: 1 | Pages: No page available

10.1111/nan.12758 | PMID 34388852 Get It

Abstract Aims The causes of distinct patterns of reduced cortical thickness in the common human epilepsies, detectable on neuroimaging and with important clinical consequences, are unknown. We investigated the underlying mechanisms of cortical thinning using a systems‐level analysis. Methods Imaging‐based cortical structural maps from a large‐scale epilepsy neuroimaging study were overlaid with highly spatially resolved human brain gene expression data from the Allen Human Brain Atlas. Cell‐type deconvolution, differential expression analysis and cell‐type enrichment analyses were used to identify differences in cell‐type distribution. These differences were followed up in post‐mortem brain tissue from humans with epilepsy using Iba1 immunolabelling. Furthermore, to investigate a causal effect in cortical thinning, cell‐type‐specific depletion was used in a murine model of acquired epilepsy. Results We identified elevated fractions of microglia and endothelial cells in regions of reduced cortical thickness. Differentially expressed genes showed enrichment for microglial markers and, in particular, activated microglial states. Analysis of post‐mortem brain tissue from humans with epilepsy confirmed excess activated microglia. In the murine model, transient depletion of activated microglia during the early phase of the disease development prevented cortical thinning and neuronal cell loss in the temporal cortex. Although the development of chronic seizures was unaffected, the epileptic mice with early depletion of activated microglia did not develop deficits in a non‐spatial memory test seen in epileptic mice not depleted of microglia. Conclusions These convergent data strongly implicate activated microglia in cortical thinning, representing a new dimension for concern and disease modification in the epilepsies, potentially distinct from seizure control.
atg7 -Based Autophagy Activation Reverses Doxorubicin-Induced Cardiotoxicity
Wang, Yong , Lu, Xiaoguang , Wang, Xiaoping , Qiu, Qi , Zhu, Ping , Ma, Lin , Ma, Xiao , Herrmann, Joerg , Wang, Wei , Lin, Xueying , Ma, Xiao , Xu, Xiaolei

Mayo Clinic

Circulation Research | August 13, 2021 | Volume: 129 | Issue: 8 | Pages: No page available

10.1161/circresaha.121.319104 | PMID 34384247 Get It

Rationale: Anthracycline-induced cardiotoxicity (AIC) is a major side effect that limits the use of anthracyclines as effective chemotherapeutics. No mechanism-based therapy is available when cardiac function deteriorates. Objective: We aim to elucidate the dynamic autophagic defects in AIC and to identify a mechanism-based therapy via both genetic and pharmacological studies. Method and Results: Through phenotyping an adult AIC zebrafish model, we detected a biphasic response in autophagy: activation in the early stage and suppression in the later phase that is characterized by a decline in cardiac function. We conducted conditional genetic studies with atg7 , which encodes a rate-limiting autophagy core protein, and found that atg7 overexpression leads to therapeutic effects in the late phase but deleterious effects in the early phase of adult AIC. We then assessed the therapeutic effects of 37 Food and Drug Administration–approved autophagy activators using an embryonic AIC zebrafish model and identified spironolactone, pravastatin, and minoxidil as top-ranking drugs. We demonstrated the therapeutic efficacy of these Food and Drug Administration–approved autophagy activators in the adult AIC model and confirmed that these drugs exert therapeutic effects in the late phase but not in the early AIC phase. Finally, we demonstrated that the time-dependent therapeutic effects are conserved in a mouse AIC model and that spironolactone and rapamycin activated autophagy in an Atg7-dependent fashion. Conclusions: Our findings suggest that atg7-based autophagy activation is an effective therapeutic avenue to reversing the decline in cardiac function in AIC, highlighting the time-dependent nature of autophagy-based therapy.
Influence of glucose levels on clinical outcome after mechanical thrombectomy for large-vessel occlusion: a systematic review and meta-analysis
Perez‐Vega, Carlos , Domingo, Ricardo A. , Tripathi, Shashwat , Kashyap, Samir , Quiñones‐Hinojosa, Alfredo , Fox, W. Christopher , Kashyap, Samir , Fox, W Christopher , Domingo, Ricardo A , Perez-Vega, Carlos , Ramos‐Fresnedo, Andres , Lin, Michelle , Tawk, Rabih G.

Mayo Clinic

Journal of NeuroInterventional Surgery | August 6, 2021 | Volume: 14 | Issue: 1 | Pages: neurintsurg-2021-017771

10.1136/neurintsurg-2021-017771 | PMID 34362794 Get It

Mechanical thrombectomy (MT) represents the mainstay of treatment for patients with acute ischemic stroke due to large-vessel occlusion (LVO). Intravenous thrombolysis has been associated with worse clinical outcome in patients presenting with high blood glucose levels at admission; to date the true effect of hyperglycemia in the setting of MT has not been fully elucidated. In this meta-analysis, we analyzed the influence of high blood glucose levels at admission on clinical outcome after MT. Ovid EMBASE, PubMed, Scopus, and Cochrane Library databases were searched from their dates of inception up to March 2021. An initial search identified 2118 articles representing 1235 unique studies. After applying selection criteria, three prospective and five retrospective studies were analyzed, yielding a pooled cohort of 5861 patients (2041 who presented with hyperglycemia, and 3820 who presented with normal blood glucose levels). Patients in the hyperglycemia group were less likely to have a modified Ranking Scale (mRS) score <3 (risk ratio (RR): 0.65; 95% CI 0.59 to 0.72; p<0.0001; I 2=13%), and had an increased risk of symptomatic intracranial hemorrhage (sICH) (RR: 2.07; 95% CI 1.65 to 2.60; p<0.0001; I 2=0%) and mortality (RR: 1.73; 95% CI 1.57 to 1.91; p<0.0001; I 2=0%). Patients who present with hyperglycemia and undergo MT for treatment of LVO have an increased risk of unfavorable clinical outcome, sICH, and mortality. Glucose levels at admission appear to be a prognostic factor in this subset of patients. Further studies should focus on evaluating control of the glucose level at admission as a modifiable risk factor in patients undergoing MT for LVO.
The impact of granulocyte colony stimulating factor on patients receiving chimeric antigen receptor T‐cell therapy
Barreto, Jason N. , Bansal, Radhika , Hathcock, Matthew , Doleski, Corina, Hayne, Justin, Truong, Tuan, Nedved, Adrienne, Ansell, Stephen M. , Lin, Yi , Johnston, Patrick B. , Doleski, Corina J, Hayne, Justin R, Truong, Tuan A, Nedved, Adrienne N, Paludo, Jonas , Lin, Yi , Hayne, Justin, Bennani, N. Nora , Paludo, Jonas , Villasboas, José C.

Mayo Clinic

American Journal of Hematology | August 5, 2021 | Volume: 96 | Issue: 10 | Pages: No page available

10.1002/ajh.26313 | PMID 34350612 Get It

Directed stimulation of the dentato-rubro-thalamic tract for deep brain stimulation in essential tremor: a blinded clinical trial
Middlebrooks, Erik H. , Okromelidze, Lela , Carter, Rickey E. , Jain, Ayushi , Lin, Chen , Westerhold, Erin , Peña, Ashley B. , Quiñones‐Hinojosa, Alfredo , Uitti, Ryan J. , Middlebrooks, Erik H , Carter, Rickey E , Grewal, Sanjeet S.

Mayo Clinic

The Neuroradiology Journal | August 3, 2021 | Volume: 35 | Issue: 2 | Pages: 203-212

10.1177/19714009211036689 | PMID 34340623 Get It

Objective Observational studies utilising diffusion tractography have suggested a common mechanism for tremor alleviation in deep brain stimulation for essential tremor: the decussating portion of the dentato-rubro-thalamic tract. We hypothesised that directional stimulation of the dentato-rubro-thalamic tract would result in greater tremor improvement compared to sham programming, as well as comparable improvement as more tedious standard-of-care programming. Methods A prospective, blinded crossover trial was performed to assess the feasibility, safety and outcomes of programming based solely on dentato-rubro-thalamic tract anatomy. Using magnetic resonance imaging diffusion-tractography, the dentato-rubro-thalamic tract was identified and a connectivity-based treatment setting was derived by modelling a volume of tissue activated using directional current steering oriented towards the dentato-rubro-thalamic tract centre. A sham setting was created at approximately 180° opposite the connectivity-based treatment. Standard-of-care programming at 3 months was compared to connectivity-based treatment and sham settings that were blinded to the programmer. The primary outcome measure was percentage improvement in the Fahn–Tolosa–Marín tremor rating score compared to the preoperative baseline. Results Among the six patients, tremor rating scores differed significantly among the three experimental conditions ( P=0.030). The mean tremor rating score improvement was greater with the connectivity-based treatment settings (64.6% ± 14.3%) than with sham (44.8% ± 18.6%; P=0.031) and standard-of-care programming (50.7% ± 19.2%; P=0.062). The distance between the centre of the dentato-rubro-thalamic tract and the volume of tissue activated inversely correlated with the percentage improvement in the tremor rating score (R 2 =0.24; P=0.04). No significant adverse events were encountered. Conclusions Using a blinded, crossover trial design, we have shown the technical feasibility, safety and potential efficacy of connectivity-based stimulation settings in deep brain stimulation for treatment of essential tremor.